Federated Hermes
PHAT icon

Federated Hermes’s Phathom Pharmaceuticals PHAT Stock Holding History

Federated Hermes’s Portfolio PHAT Stock Details PHAT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-549
Closed -$9.11K – 2143
2025
Q4 		$9.11K Buy
+549
New +$7.84K ﹤0.01% 1840
2024
Q4 		– Sell
-1,403,638
Closed -$25.4M – 2165
2024
Q3 		$25.4M Buy
+1,403,638
New +$19.6M 0.06% 373
2023
Q4 		– Sell
-82,148
Closed -$852K – 2168
2023
Q3 		$852K Sell
82,148
-81,808
-50% -$1.12M ﹤0.01% 1170
2023
Q2 		$2.35M Buy
+163,956
New +$1.89M 0.01% 905

Other funds holding PHAT

FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
MVM
Medicxi Ventures Management St. Helier, Jersey $982M AUM 210.17% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
CG
Carlyle Group Washington, District of Columbia $10.6B AUM 11.25% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
Ensign Peak Advisors
Ensign Peak Advisors Salt Lake City, Utah $53.7B AUM 29.47% 1-Year Est. Return

Federated Hermes's PHAT Position: Q1 2026 in Review

Federated Hermes sold out of Phathom Pharmaceuticals (PHAT) in Q1 2026, closing a stake of 549 shares — an estimated $9.11K sold.

Federated Hermes first reported a position in PHAT in Q2 2023 and held it in 4 quarters. The position peaked at $25.4M in Q3 2024. 174 funds tracked by Wall St. Rank hold PHAT as of Q1 2026.

  • Federated Hermes reported no remaining Phathom Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Federated Hermes sold 549 Phathom Pharmaceuticals shares in Q1 2026, an estimated $9.11K.
  • Federated Hermes first reported a position in Phathom Pharmaceuticals in Q2 2023 and held it in 4 quarters.
  • Federated Hermes's Phathom Pharmaceuticals position peaked at $25.4M in Q3 2024.
  • 174 funds tracked by Wall St. Rank held Phathom Pharmaceuticals as of Q1 2026.

Based on Federated Hermes's 13F filing for Q1 2026, filed 11 May 2026.